Total PCBsa | CYP1A1 M1 genotype | All participants | Premenopausal | Postmenopausal | |||
---|---|---|---|---|---|---|---|
 |  | Patients/controls | OR (95% CI)b | Patients/controls | OR (95% CI)b | Patients/controls | OR (95% CI)b |
African Americans | Â | Â | Â | Â | Â | Â | Â |
<0.430 | Non-M1 | 66/75 | Referent | 46/51 | Referent | 20/24 | Referent |
≥0.430 | Non-M1 | 75/67 | 1.5 (0.9–2.5) | 21/16 | 1.9 (0.9–4.2) | 54/51 | 1.0 (0.5–2.3) |
<0.430 | Any M1 | 42/46 | 1.0 (0.6–1.7) | 35/33 | 1.2 (0.6–2.2) | 7/13 | 0.6 (0.2–1.8) |
≥0.430 | Any M1 | 59/54 | 1.4 (0.8–2.5) | 17/14 | 1.7 (0.8–4.1) | 42/40 | 1.0 (0.5–2.3) |
ICR (95% CI) | Â | Â | 0.0 (-0.9,0.9) | Â | -0.3 (-2.2,1.6) | Â | 0.4 (-0.5,1.3) |
Whites | Â | Â | Â | Â | Â | Â | Â |
<0.349 | Non-M1 | 174/133 | Referent | 118/83 | Referent | 56/50 | Referent |
≥0.349 | Non-M1 | 122 148 | 0.7 (0.5–1.0) | 38/43 | 0.6 (0.4–1.1) | 84/105 | 0.8 (0.5–1.3) |
<0.349 | Any M1 | 45/44 | 0.8 (0.5–1.2) | 29/31 | 0.7 (0.4–1.2) | 16/13 | 1.1 (0.5–2.5) |
≥0.349 | Any M1 | 29/32 | 0.8 (0.4–1.4) | 11/10 | 0.7 (0.3–1.9) | 18/22 | 0.8 (0.4–1.7) |
ICR (95% CI) | Â | Â | 0.4 (-0.2,0.9) | Â | 0.5 (-0.3,1.2) | Â | 0.0 (-1.1,1.0) |